Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2012

View Archived Issues

Research at Merck Frosst Canada yields new HIV protease inhibitors

Merck KGaA discloses new PI3K inhibitors

Long-term results with Lenti-D reported

Takeda reviews achievements of fiscal 2011

Researchers describe preclinical and phase I results with AQX-1125

Cardioprotection observed with novel bivalent engineered neuregulin 1B protein

Secretin relieves pain in chronic pancreatitis patients

Novel Anacor Pharmaceuticals compound reduces inflammation in vivo

DPT-NX7 induces regressions in squamous cell carcinoma model

Lupin designs new CRAC channel modulators

Novel Abeta production inhibitors created at Dainippon Sumitomo

FDA includes 156-week data in new Isentress labeling

Canadian universities develop novel antibiotics

Kinex out-licenses rights to KX-02 in greater China territory

Peregrine Pharmaceuticals reports data from phase IIb study in NSCLC

New iPierian programs target Tau protein and complement pathway

Oxford BioTherapeutics presents new diagnostic antibodies

Daiichi Sankyo and the Japanese National Cancer Center enter anticancer collaboration

Achillion reports new proof-of-concept data for ACH-2684

CHDI Foundation to conduct preclinical research on Lundbeck compound

Cerecor commences exploratory trial of FP-01

Phase III MISSION trial misses primary endpoint

Third phase III trial of Sativex in cancer pain begins

Medivation submits NDA for enzalutamide

Enrollment complete in phase I trial of MOR-208

Phase IIb trial of Catalyst's treatment candidate for cocaine addiction reaches target enrollment

Cellceutix gives update on IND for novel p53 anticancer drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...